Oregon State Hammering out Rules for Legal Psilocybin Therapy
While Oregonians voted to legalize psilocybin therapy back in November 2020, officials there are still ironing out the regulations for this new chapter in mental health resources for the state.
A state-appointed advisory board, which was formed in March 2021, has been researching all aspects of psilocybin therapy in order to recommend regulations for the Oregon Health Authority (OHA). Once they’ve approved the recommendations, the OHA will take on license applications by the last day of the year, December 31, 2022, assuming there aren’t any more delays.
Psilocybin would only be available through licensed sources
Unlike legalized cannabis, psilocybin won’t be available for purchase at dispensaries. Instead, licenses will be provided for psilocybin facilitators, clinics, producers and distributors.
Based on the advisory board’s recommendations, the OHA has proposed rules that relate to issues around psilocybin products, testing and proper training for facilitators.
Medicine would be limited to derivatives of Psilocybe cubensis
The board proposed that any psilocybin products must be derived from Psilocybe cubensis, the most commonly consumed psilocybin mushroom species.
The report noted additional risks raised by genetically-modified psilocybin, but did not explain the basis for its later recommendation against the use of synthetic psilocybin. It also suggested that psilocybin products could lead to adverse reactions when combined with other drugs or adulterants, such as cannabis or alcohol.
Administration would be limited to dried or edible form
In terms of how the mushrooms could be produced and sold, the board recommends that they be limited to their mushroom form or as edible products taken orally. The active ingredient, psilocybin, would be allowed to be extracted.
However, the board recommended prohibiting psilocybin products in the form of patches, inhalers, nasal sprays and suppositories. And much like regulation around cannabis products, psilocybin products wouldn’t be allowed to be sold or marketed in a different form that appeals to children
Cultivation would be subject to lab testing and recording of protocols
The proposal also zeros in on the specific material that the mushrooms are grown in, recommending “food grade material” and prohibiting the use of wood chips or dung. Additionally, the board advised that synthetic and genetically modified psilocybin not be permitted.
In a July 2021 report, the advisory board made the recommendation for Psilocybe cubensis and “grain-based” cultivation material as a result of “toxicity concerns” with other species and materials.
Under the proposed rules, producers would also need to submit testing of mushroom batches to labs to check for potency, solvents like pesticides, microbes such as E. coil and heavy metals, such as lead. Protocols for manufacturing, lab reports, and other relevant information would need to be recorded.
Oregon’s psilocybin status is still in its implementation phase
Oregon is still in the two-year implementation phase before the new legal status becomes official. It is the first state in the U.S. to work towards both the decriminalization and legalization of psilocybin for therapeutic purposes.
This article is for informational purposes only and is not intended to be a substitute for professional medical advice. Always talk to your doctor about the risks and benefits of any treatment. If you are in a life-threatening situation, call the National Suicide Prevention Line at +1 (800) 273-8255, call 911, or go to the nearest emergency room.
Ketamine is not FDA-approved for the treatment of depression or anxiety. Learn more about off-label uses here.
Side effects of ketamine treatment may include: altered sense of time, anxiety, blurred vision, diminished ability to see/hear/feel, dry mouth, elevated blood pressure or heart rate, elevated intraocular or intracranial pressure, excitability, loss of appetite, mental confusion, nausea/vomiting, nystagmus (rapid eye movements), restlessness, slurred speech, synesthesia (a mingling of the senses).
Do not proceed with ketamine treatment if any of the following apply to you:
- Allergic to ketamine
- Symptoms of psychosis or mania
- Uncontrolled high blood pressure
- CHF or other serious heart problem
- Severe breathing problem
- History of elevated intraocular or intracranial pressure
- History of hyperthyroidism
- Other serious medical illness
- Pregnant, nursing, or trying to become pregnant
Ketamine has been reported to produce issues including, but not limited to, those listed below. However, lasting adverse side-effects are rare when medical protocols are carefully followed.
While ketamine has not been shown to be physically addictive, it has been shown to cause moderate psychological dependency in some recreational users.
- In rare cases, frequent, heavy users have reported increased frequency of urination, urinary incontinence, pain urinating, passing blood in the urine, or reduced bladder size
- Ketamine may worsen problems in people with schizophrenia, severe personality disorders, or other serious mental disorders.
- Users with a personal or family history of psychosis should be cautious using any psychoactive substance, including ketamine, and discuss potential risks with your MindBloom® clinician before proceeding with treatment.
- The dissociative effects of ketamine may increase patient vulnerability and the risk of accidents.
To promote positive outcomes and ensure safety, follow these ketamine treatment guidelines:
- Do not operate a vehicle (e.g., car, motorcycle, bicycle) or heavy machinery following treatment until you’ve had a full night of sleep
- Refrain from taking benzodiazepines or stimulants for 24 hours prior to treatment
- Continue to take antihypertensive medication as prescribed
- Avoid hangovers or alcohol intake
- Refrain from consuming solid foods within 3 hours prior to treatment and liquids within 1 hour prior to treatment
- Ketamine treatment should never be conducted without a monitor present to ensure your safety